NCT03690869: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

NCT03690869
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: Up to 25 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Phase I
Exclusions: Patients older than 18 years of age
https://ClinicalTrials.gov/show/NCT03690869

Comments are closed.

Up ↑